Study Finds Surgery Effective for Patients with Aggressive Prostate Cancer - Mayo Clinic
Study Finds Surgery Effective for Patients with Aggressive Prostate Cancer - Mayo Clinic
Stephen A. Boorjian, M.D., of the Department of Urology at Mayo Clinic discusses a study of the outcomes after treatment for patients with high-risk prostate cancer. Patients with the most aggressive forms of prostate cancer who had radical prostatectomy procedures had a 10-year cancer-specific survival rate of 92 percent and an overall survival rate of 77 percent. The cancer-specific survival rate for patients who had radiation therapy alone was 88 percent and the overall survival rate was 52 percent. Learn more about prostate cancer care at Mayo Clinic: https://mayocl.in/35upagcTo request an appointment at Mayo Clinic, visit: https://mayocl.in/2lYscYA
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.